Vertex Pharmaceuticals Aktie News

Healthcare stocks have struggled since interest rates began climbing in 2022. Rising yields pulled capital away from speculative biotech and drug development, pushing valuations lower even as research pipelines advanced.

Warren Buffett famously said that he and his investing managers "attempt to be fearful when others are greedy, and to be greedy only when others are fearful." With the stock market near a record high, many investors are a lot greedier than they are fearful right now.

Earlier this year, all three major indexes -- the S&P 500, the Nasdaq, and the Dow Jones Industrial Average -- slid as President Donald Trump announced his plan to impose tariffs on imports. Investors worried this would result in higher costs for U.S. companies as they import their goods made abroad -- and this might sink earnings.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2025 financial results on Monday, November 3, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Th...

Equity markets are said to be forward looking. However, sometimes they fail to look far enough into the future by reacting too harshly to the challenges some companies face in the present.

As we enter the final three months of 2025, some investors may be looking for red-hot growth stocks with room to run. Whereas others may be searching for beaten-down stocks at compelling valuations to boost their passive income.

President Donald Trump delivered the pharmaceutical industry another blow this week, threatening 100% tariffs on some companies.

Even amid political pressure from RFK Jr. and President Trump, as well as failed clinical data on VX-993, Vertex continues to strengthen its position in the cystic fibrosis market. Sales of its three key drugs, Trikafta, Kaftrio, and Alyftrek, which are part of the CF portfolio, reached about $2.71 billion in the second quarter of 2025, up 10.6% year-on-year. On the positive side, Vertex's oper...